FDA urges healthcare providers to not use sterile drug products from Medaus

The Food and Drug Administration issued a reminder to healthcare providers May 5, reminding them not to use sterile drugs produced by Birmingham, Ala.-based Medaus, as the products may be risky to patients.

The FDA also issued a formal request to the compounding pharmacy to recall its products that are intended to be sterile. The drugs include hormone replacement products and injectable nutritional products like vitamins and amino acids.

All of this stems from an FDA inspection of Medaus' facilities in March, during which the agency found unsanitary conditions. Following that inspection, the FDA asked the company in March to recall non-expired lots of those products, but Medaus refused to do so. The FDA also warned healthcare professionals not to use the products in April.

"Patient safety is our top priority and patients deserve drugs that are made under safe conditions," said Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research. "We are deeply concerned about the safety of the products made by Medaus and the risks associated with them."

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars